News
Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation
Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports biomarker data from the ongoing
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca data being presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium 2021. These include
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update.
“We made significant
QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the fourth quarter and full-year 2020, exceeding the goals for net sales and adjusted earnings per
QIAGEN übertrifft Prognose für das vierte Quartal und das Gesamtjahr 2020 und bestätigt die Erwartung für weiteres Wachstum in 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute starke Ergebnisse der operativen Tätigkeit für das vierte Quartal und das Gesamtjahr 2020 bekannt. Das Unternehmen hat seine Ziele
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
QUANTUM GENOMICS : Orient EuroPharma Acquires Equity Stake in Quantum Genomics
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs that directly targets the brain to treat difficult-
Novocure Announces Addition to Its Board of Directors
Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5.
“We are extremely
Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer
Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.
In connection with the
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter 2020 and full-year 2020, raised 2021 guidance(4) for Adjusted diluted EPS(2) and provided 2021 financial guidance(4) for other
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer
QIAGEN erweitert wachsendes Portfolio von COVID-19 Testlösungen um dPCR-Plattform QIAcuity für Abwasser- und Mutationstests
QIAGEN gab heute bekannt, dass das wachsende Portfolio an COVID-19-Produkten um Kits für Abwassertests ergänzt wird. Der Einsatz der Digitalen PCR (dPCR) bei der weltweiten Überwachung von COVID-19